Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Cancer Res. 2009 Nov 17;69(23):8941–8948. doi: 10.1158/0008-5472.CAN-09-1828

Figure 1.

Figure 1

A, In vitro kill of NT2.5 breast cancer cells by 225Ac-7.16.4. NT2.5 cells were treated with 225Ac-7.16.4 for 3 days (open circle), 5 days (closed triangle), or with the presence of 50 μg/ml unconjugated 7.16.4 (open diamond). 225Ac-Rituximab was used as non-specific control to treat NT2.5 cells for 5 (open triangle) or 3 (open square) days. Survival fraction was calculated by dividing the number of colonies in treatment groups over that in the untreated control group.

B, Biodistribution of 225Ac-7.16.4 in neu-N mice at decay equilibrium; data are presented as percent injected dose per gram (%ID/g±SD). Biodistributions of free 213Bi (C) and 221Fr (D) in major organs (at 1 hr) are shown at the time of sacrifice and decay equilibrium. Star (*) marks the difference that is statistically significant; data are expressed as Bq per gram (Bq/g±SD).